Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2027, 2028, and 2029 (P50 Clinical Trial Required)

The National Cancer Institute, potentially in collaboration with the National Institute of Dental and Craniofacial Research, is soliciting applications for P50 Research Center Grants for Specialized Programs of Research Excellence. This program supports investigator-initiated translational research focused on the prevention, early detection, diagnosis, and treatment of organ-specific cancers or closely related cancer groups. Eligible research must be grounded in human biology using genetic, molecular, biochemical, structural, or cellular experimental approaches and must achieve a translational human endpoint within the grant period. Under solicitation number PAR-28-022, this opportunity covers the years 2027, 2028, and 2029 and requires the inclusion of clinical trials. The notice was posted on October 14, 2026, with a final response deadline of September 26, 2029. This initiative serves as a re-issuance of PAR-23-284 to continue funding state-of-the-art research aimed at improving clinical outcomes for cancer patients.